
# Optimapharm Connect



Dear Industry Colleges,

Welcome to Optimapharm's newsletter! We are delighted to, periodically, share our news and knowledge with you and we welcome you feedback!

As the CEO of Optimapharm, I have the privilege to work, daily, with an exceptional team of Optimapharm's professionals who are here to serve our clients, and ultimately our patients, with the utmost dedication. Our practical motto "We deliver on your promises" is a way of living and working for us. We recognize that our clients have made promises to their stakeholders: patients, employees, shareholders, investors, and others. We are here to support you, our clients, to deliver on your promises!

Our team is motivated because we passionately care about what we do – that is the basis for our shared identity, as one team!

As we have already entered the last quarter of 2023, I reflect on the whirlwind year it has been so far. We have embraced challenges, overcame obstacles, and celebrated many successes. It is important to keep in mind that we can rely on each other and grow together through all the experiences. We keep the purpose in mind. The purpose of showing up, every day, intentionally, for the benefit of our clients and patients.

One of the clients that we are working with on a pediatric study always talks about "our babies". These patients are not 'just' study subjects to them, they are "their babies" -

they are our babies! Strong reminder of why we do what we do! Sincerely yours,

Ivana

### **QUARTERLY HIGHLIGHTS**



117

sites initiated in 20 countries in Celiac Disease, Phase II study



2

studies with patient enrolment completed – Seasonal Allergic Rhinitis in Phase II and Aortic stenosis study



1

First patient in Agerelated macular degeneration (AMD), Phase III study



2

studies successfully closed: Prostate

Cancer - Phase II/III, and Acute Myeloid

Leukemia (AML) - Phase I/II



2

study database lock milestone completed – Ovarian cancer Medical Device Phase III and Acute Myelogenous Leukemia Phase III




### Optimapharm announces Jelena Pavlović as Senior Director, Trial Support

To continue delivering high-quality service to its clients, Optimapharm team joined Jelena Pavlović to lead Trial Support department.

Jelena brings over 20 years of experience in global clinical trial operations and is highly experienced in eTMF process development (including Veeva Vault and Medidata RAVE) and their global implementation and integration with other clinical trial management systems.

Find out more






## Dare to walk off the old path in cancer clinical trials!

Lately, the conventional sequential model of cancer clinical research is being replaced by adaptive trial designs, in which separate trial phases may be combined in a single protocol, thus accelerating drug development, and optimizing the use of available resources.

Gain new insights in Optimapharm's expert Dionysios Palermos article published in the Journal of Clinical Medicine.

Read the paper



### **Oncology Experience**

The oncology trials in various indications represent the largest portion of clinical trials conducted by Optimapharm.

Did you know that we have:

successfully completed over 380 oncology trials in phases I-III including complex medical devices

306 highly educated, experienced, and productive team members with oncology experience

Read our Factsheet Oncology and get more familiar with our expertise.

**Explore** more

### Meet with our experts at an upcoming conferences



In the next month, our experts will be attending leading industry conferences:

- OCT DACH 2023, 21-22 November, Zurich, Switzerland
- Nordic Life Science Days 2023, 29-30 November, Copenhagen, Denmark

If you are attending, don't miss the opportunity to meet with our experts in person to discuss how we can support your upcoming clinical projects!

Reach out to us and book a meeting with our team members!

Schedule a meeting

Find out how We Deliver on Your Promises







#### **Optimapharm**

You received this email because you signed up on our website or communicated with a member of our team. If you wish to refrain from receiving quarterly newsletters from Optimapharm, please unsubscribe. To understand how we use your personal information, please see our privacy policy.

Copyright 2023 Optimapharm. All rights reserved.

Unsubscribe